Health Care & Life Sciences » Healthcare Provision | Shin Nippon Biomedical Laboratories Ltd.

Shin Nippon Biomedical Laboratories Ltd. | Balance Sheet

Fiscal year is April-March. All values JPY Millions.
2014
2015
2016
2017
2018
2019
Cash & Short Term Investments
9,752
7,276
4,942
7,447
5,313
5,142
Total Accounts Receivable
2,756
3,127
3,107
2,843
2,547
1,914
Inventories
5,366
7,593
7,315
6,966
6,439
3,600
Other Current Assets
876
1,014
941
890
991
1,011
Total Current Assets
18,750
19,011
16,306
18,146
15,290
11,666
Net Property, Plant & Equipment
19,205
19,543
19,894
17,105
14,654
13,687
Total Investments and Advances
1,175
1,298
10,438
19,069
26,070
27,619
Long-Term Note Receivable
71
70
1,065
1,060
1,035
1,032
Intangible Assets
206
195
342
371
289
93
Other Assets
428
373
196
486
259
222
Total Assets
39,906
40,552
48,241
56,253
57,608
54,329
ST Debt & Current Portion LT Debt
8,493
10,832
10,543
11,823
11,730
Accounts Payable
57
73
153
87
85
Income Tax Payable
789
847
1,405
176
182
Other Current Liabilities
6,592
7,573
7,395
7,590
8,006
Total Current Liabilities
15,931
19,325
19,496
19,676
20,003
Long-Term Debt
13,394
11,517
12,005
11,298
7,409
Deferred Taxes
56
53
203
2,678
3,879
Other Liabilities
50
55
61
112
91
Total Liabilities
29,391
30,908
31,766
33,780
31,393
Common Equity (Total)
10,433
9,617
16,447
22,451
26,159
Total Shareholders' Equity
10,433
9,617
16,447
22,451
26,159
Total Equity
10,515
9,644
16,475
22,473
26,216
Liabilities & Shareholders' Equity
39,906
40,552
48,241
56,253
57,608
Accumulated Minority Interest
82
27
28
22
57

About Shin Nippon Biomedical Laboratories

View Profile
Address
St. Luke's Tower, 12/F
Tokyo Tokyo 104
Japan
Employees -
Website http://www.snbl.co.jp
Updated 07/08/2019
Shin Nippon Biomedical Laboratories, Ltd. is a contract research organization providing drug development services including safety research, clinical pharmacology, and clinical trials. Its operations are carried out through the following segments: Preclinical Business, Clinical Business, Translational Research Business, Medipolis Business, and Others. The Preclinical Business segment verifies the efficacy and safety of new drugs using experimental animals and bacterial cells.